Mostrar el registro sencillo del ítem

dc.contributor.authorBahia, Luciana Ribeiropt_BR
dc.contributor.authorRosa, Michelle Quarti Machado dapt_BR
dc.contributor.authorAraújo, Denizar Viannapt_BR
dc.contributor.authorCorreia, Marcelo Goulartpt_BR
dc.contributor.authorRosa, Roger dos Santospt_BR
dc.contributor.authorDuncan, Bruce Bartholowpt_BR
dc.contributor.authorToscano, Cristiana Mariapt_BR
dc.date.accessioned2019-08-16T02:31:12Zpt_BR
dc.date.issued2019pt_BR
dc.identifier.issn1758-5996pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/198064pt_BR
dc.description.abstractBackground : Diabetes and its complications produce significant clinical, economic and social impact. The knowledge of the costs of diabetes generates subsidies to maintain the financial sustainability of public health and social security systems, guiding research and health care priorities. Aims: The aim of this study was to estimate the economic burden of diabetes in Brazilian adults in 2014, considering the perspectives of the public health care system and the society. Methods: A prevalence-based approach was used to estimate the annual health resource utilization and costs attributable to diabetes and related conditions. The healthcare system perspective considered direct medical costs related to outpatient and hospitalization costs. The societal perspective considered non-medical (transportation and dietary products) and indirect costs (productivity loss, disability, and premature retirement). Outpatient costs included medicines, health professional visits, exams, home glucose monitoring, ophthalmic procedures, and costs related to end stage renal disease. The costs of hospitalization attributed to diabetes related conditions were estimated using attributable risk methodology. Costs were estimated in Brazilian currency, and then converted to international dollars (2014). Results: Based on a national self-reported prevalence of 6.2%, the total cost of diabetes in 2014 was Int$ 15.67 billion, including Int$ 6.89 billion in direct medical costs (44%), Int$ 3.69 billion in non-medical costs (23.6%) and Int$ 5.07 billion in indirect costs (32.4%). Outpatient costs summed Int$ 6.62 billion and the costs of 314,334 hospitalizations attributed to diabetes and related conditions was Int$ 264.9 million. Most hospitalizations were due to cardiovascular diseases (47.9%), followed by diabetes itself (18%), and renal diseases (13.6%). Diet and transportation costs were estimated at Int$ 3.2 billion and Int$ 462.3 million, respectively. Conclusions: Our results showed a substantial economic burden of diabetes in Brazil, and most likely are underrated as they are based on an underestimated prevalence of diabetes. Healthcare policies aiming at diabetes prevention and control are urgently sought.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofDiabetology & metabolic syndrome. London. vol. 11, (2019), 54, 9 f.pt_BR
dc.rightsOpen Accessen
dc.subjectDiabetes mellitus tipo 2pt_BR
dc.subjectType 2 diabetesen
dc.subjectEfeitos psicossociais da doençapt_BR
dc.subjectCost analysisen
dc.subjectCost studiesen
dc.subjectSaúde públicapt_BR
dc.subjectPublic healthen
dc.titleEconomic burden of diabetes in Brazil in 2014pt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001097804pt_BR
dc.type.originEstrangeiropt_BR


Ficheros en el ítem

Thumbnail
   

Este ítem está licenciado en la Creative Commons License

Mostrar el registro sencillo del ítem